MARKHAM, ON--(Marketwire - August 16, 2010) - Axxess Pharma, Inc. (PINKSHEETS: AXXE), a pharmaceutical company specializing in the marketing and distribution of both prescription and non-prescription medical products, is pleased to report they have generated $1.3 million in annual sales from their non-constipating multi-vitamin Triferrex 150.
Patients and individuals around the world frequently experience constipation from multi-vitamins due to high iron and calcium contents. This uncomfortable feel often times makes patients and individuals refuse to take the multi-vitamins that are needed to keep them healthy or return to health. This action then places the patient in further harm. Triferrex 150 helps eliminate this problem by providing the careful balance of required nutrients while preventing constipation.
"Sales for Triferexx 150 have surpassed our expectations. We forecasted $1 million in sales for 2009 and ended with $1.3 million. We anticipate 2010 sales of Triferrex 150 to exceed that of 2009. The Specialists and the general practitioners have accepted Triferexx 150 as a safe and a well tolerated Iron supplement than the other iron preparations in the market. Triferexx 150 is prescribed by the leading nephrologistas, a hematenic of choice in conjunction with Eperex at the dialysis clinics," stated Gerald Sequeira, President/CEO.
For more information, please contact Investor Relations at (973) 351-3868.
About Axxess Pharma, Inc.:
Axxess Pharma, Inc. is a specialty pharmaceutical company that focuses on the marketing of dermatological, therapeutic nutritionals, pain management and diagnostic products in Canada and abroad since 1997. Axxess owns 22 established pharmaceutical prescription products that have proven sales in Canada and internationally. The company has an experienced management team and field sales force to market products nationally to hospitals and retail pharmacies as well as specialized practice areas including Dermatology and Nephrology, Neurology and Urology.
Statements about the Company's future expectations and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby.
The above information contains information relating to the Company that is based on the beliefs of the Company and/or its management, as well as assumptions made by any information currently available to the Company or its management. When used in this document, the words "anticipate," "estimate," "expect," "intend," "plans," "projects," and similar expressions, as they relate to the Company or its management, are intended to identify forward-looking statements. Such statements reflect the current view of the Company regarding future events and are subject to certain risks, uncertainties and assumptions, including the risks and uncertainties noted. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove to be incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, intended or projected. In each instance, forward-looking information should be considered in light of the accompanying meaningful cautionary statements herein. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, the impact of competitive services and pricing and general economic risks and uncertainties.